<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04511507</url>
  </required_header>
  <id_info>
    <org_study_id>Cyto-ALF</org_study_id>
    <nct_id>NCT04511507</nct_id>
  </id_info>
  <brief_title>CytoSorb in Patients With Liver Failure</brief_title>
  <official_title>Effects of Renal Replacement Therapy With Hemoadsoption in Patients With Liver Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institutul Clinic Fundeni</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institutul Clinic Fundeni</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hemoadsorption has been demonstrated to improve liver functional tests in patients with liver&#xD;
      failure. The present study investigates the effects of three consecutive sessions of&#xD;
      hemoadsorption, performed in accordance to the local protocol for treating patients with&#xD;
      acute liver failure, on liver functional tests, severity scores and 30-days mortality.&#xD;
      Paraclinical results and severity scores were obtained before and after the three consecutive&#xD;
      sessions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 10, 2016</start_date>
  <completion_date type="Actual">August 30, 2021</completion_date>
  <primary_completion_date type="Actual">August 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>30 days mortality</measure>
    <time_frame>30 days</time_frame>
    <description>30 days mortality</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">35</enrollment>
  <condition>Liver Dysfunction</condition>
  <arm_group>
    <arm_group_label>liver failure</arm_group_label>
    <description>patients diagnosed with acute liver failure or acute on chronic liver failure in accordance with national guidelines who require 3 consecutive sessions of hemoadsorption</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>hemoadsorption</intervention_name>
    <description>three consecutive sessions of hemoadsorption in patients with liver failure</description>
    <arm_group_label>liver failure</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        - patients with acute liver failure or acute on chronic liver failure who require&#xD;
        hemoadsorption in accordance with local guidelines. The decision of hemoadsorption is made&#xD;
        by the attending physician prior to study inclusion.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients with acute liver failure or acute on chronic liver failure who require&#xD;
             hemoadsorption in accordance with local guidelines&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  unsigned informed consent&#xD;
&#xD;
          -  duration of therapy under 12 hours&#xD;
&#xD;
          -  death before the three consecutive sessions&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dana Tomescu, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Fundeni Clinical Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fundeni Clinical Institute</name>
      <address>
        <city>Bucharest</city>
        <zip>022328</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Romania</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 11, 2020</study_first_submitted>
  <study_first_submitted_qc>August 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2020</study_first_posted>
  <last_update_submitted>September 3, 2021</last_update_submitted>
  <last_update_submitted_qc>September 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institutul Clinic Fundeni</investigator_affiliation>
    <investigator_full_name>Popescu Mihai</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

